Challenges of Conducting Clinical Trials in Rare Hematologic Disorders: A focus on hematopoietic cell transplantation.

Hematopoietic cell transplant (HCT) is a life-saving treatment option for patients with rare blood and marrow disorders. Using blood or marrow cells from a related or unrelated donor is a therapeutic approach that has been undergoing research predating the first HCT performed in 1956. As the HCT field has evolved with further understanding of the biological mechanisms, there remain numerous questions that need to be addressed due to the heterogeneous group of disorders, variety of treatment modalities, and complex relationship of competing outcomes in the post-HCT period.

Research is always improving medical practices, and in a new Whitepaper, we go into detail surrounding one treatment we have been working on since 1995.

What’s Inside:

 

  • Impact of HCT on Patients and Families
  • Site Selection and Recruitment
  • Flexible Eligibility Criteria
  • Trial Monitoring
  • Statistical Analysis
  • Conclusion

    Do you have a clinical trial currently at risk? YesNo

    Do you have an upcoming clinical trial? YesNo